[Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].

Sequence of the gene encoding a plasmid-mediated cefotaxime-hydrolyzing class A beta-lactamase (CTX-M-4): involvement of serine 237 in cephalosporin hydrolysis. Antimicrob Agents Chemother (1998) 3.34

A plasmid-mediated beta-lactamase conferring resistance to cefotaxime in a Salmonella typhimurium clone found in St Petersburg, Russia. J Antimicrob Chemother (1998) 1.79

Misidentification of alpha-hemolytic streptococci by routine tests in clinical practice. Infect Genet Evol (2011) 1.31

Fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Russia: molecular mechanisms implicated. J Antimicrob Chemother (2004) 1.07

Discrimination between Streptococcus pneumoniae and Streptococcus mitis based on sorting of their MALDI mass spectra. Clin Microbiol Infect (2013) 1.03

[MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones]. Antibiot Khimioter (2007) 1.00

[Genetic determinants of antibacterial resistance among nosocomial Escherichia coli, Klebsiella spp., and Enterobacter spp. isolates collected in Russia within 2003-2007]. Antibiot Khimioter (2010) 0.85

[Genetic environments of bla(CTX-M) genes located on conjugative plasmids of Enterobacteriaceae nosocomial isolates collected in Russia within 2003-2007]. Antibiot Khimioter (2010) 0.82

[Dynamics of Streptococcos pneumoniae antibiotic resistance extension in Moscow in 1998-2003]. Antibiot Khimioter (2004) 0.81

[Antibiotic Resistance and Serotype Pattern of Streptococcus pneumoniae Isolated from Children in St. Petersburg in 2010-2013]. Antibiot Khimioter (2015) 0.79

First detection of VIM-4 metallo-β-lactamase-producing Escherichia coli in Russia. Clin Microbiol Infect (2012) 0.79

[The chemotherapeutic efficacy of ciprofloxacin and lomefloxacin in the inhalation method of infecting white mice with tularemia]. Antibiot Khimioter (2000) 0.79

[Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections]. Antibiot Khimioter (2003) 0.78

[Development of a PCR-based method for diagnostics of mycoses]. Mol Gen Mikrobiol Virusol (2003) 0.78

[Staphylococcal cassette chromosome mec, evolution and genetic lines of methicillin resistant Staphylococcus aureus]. Antibiot Khimioter (2012) 0.77

[Susceptibility of gramnegative carbapenemase-producing bacteria to various group antibiotics]. Antibiot Khimioter (2013) 0.77

[Antibiotic Resistance of MRSA in the Russian Federation]. Antibiot Khimioter (2015) 0.76

[A mass-spectrometric analysis of genetic markers of S. pneumoniae resistance to beta-lactam antibiotics]. Mol Gen Mikrobiol Virusol (2010) 0.76

Effects of Ouabain on Proliferation of Human Endothelial Cells Correlate with Na+,K+-ATPase Activity and Intracellular Ratio of Na+ and K. Biochemistry (Mosc) (2016) 0.76

[Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study]. Antibiot Khimioter (2002) 0.76

[Treatment of intestinal dysbacteriosis in children with diabetes mellitus]. Antibiot Khimioter (1999) 0.75

[Comparative in vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antibiotics with respect to staphylococci and pneumococci]. Antibiot Khimioter (1995) 0.75

[Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods]. Antibiot Khimioter (2007) 0.75

[8th Mediterranean congress on chemotherapy]. Antibiot Khimioter (1994) 0.75

[Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I]. Antibiot Khimioter (2005) 0.75

[Microturbidimetric method for determining the activity of polymyxin M]. Antibiot Khimioter (1994) 0.75

[Protective properties of doxycycline, rifampicin and sisomycin in experimental pulmonary tularemia of albino mice]. Antibiot Khimioter (1998) 0.75

[Extended release fluoroquinolone formulations]. Antibiot Khimioter (2004) 0.75

[Ceftriaxone in the treatment of purulent meningitis]. Antibiot Khimioter (1996) 0.75

[Synthesis and antibacterial activity of new polyfluoro-1,3,5-oxadiazines]. Antibiot Khimioter (2005) 0.75

[Epidemiology of mycosis and pathogen susceptibility to antimycotics]. Antibiot Khimioter (2007) 0.75

[Detection of the determinants of tetracycline A, B and C resistance in Shigella and Salmonella using DNA probes]. Antibiot Khimioter (1991) 0.75

[Fifth European congress on clinical microbiology and infectious diseases]. Antibiot Khimioter (1993) 0.75

[Ceftriaxone: whether there is future for it?]. Antibiot Khimioter (2006) 0.75

[Multicenter trial of Enterococcus antibiotic susceptibility]. Antibiot Khimioter (1998) 0.75

[Comparative in vitro activity ampicillin, cefoperazone, their combinations with sulbactam, as well as that of other antibiotics against aerobic gram-negative microorganisms]. Antibiot Khimioter (1994) 0.75

[Indices of lipid metabolism in children with dysmetabolic nephropathy undergoing balneotherapy with nitric-silicon thermal water]. Vopr Kurortol Fizioter Lech Fiz Kult (2008) 0.75

[Use of mathematical theory in experiments evaluating the protective properties of antimicrobial preparations]. Antibiot Med Biotekhnol (1986) 0.75

[Current problems of diagnosis and treatment of tuberculosis]. Antibiot Khimioter (1999) 0.75

[Dynamics of beta-lactams resistance distribution in Streptococcus pneumoniae and its clinical significance]. Antibiot Khimioter (2010) 0.75

[In vitro study of antimicrobial activity of lactoferrins from various sources]. Antibiot Khimioter (2010) 0.75

[Resistance epidemiology of gramnegative nonfermenting pathogens of nosocomial infections in intensive care units and surgical departments]. Antibiot Khimioter (2006) 0.75

[Antimicrobial prophylaxis of surgical wound infections]. Antibiot Khimioter (2005) 0.75

[Antimicrobial susceptibility and molecular mechanisms of resistance to beta-lactams of gram-negative microorganisms--causative agents of nosocomial infections]. Zh Mikrobiol Epidemiol Immunobiol (2007) 0.75

[Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis]. Antibiot Khimioter (2006) 0.75

[Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm']. Antibiot Khimioter (2007) 0.75

[Hospital infections caused by Pseudomonas aeruginosa. Spread and clinical importance of antibiotic resistance]. Antibiot Khimioter (1999) 0.75

Development of local morphological changes after intradermal inoculation of Q-fever chemovaccine. Acta Virol (1989) 0.75

[Effect of antibiotics on Francisella tularensis]. Antibiot Khimioter (1992) 0.75

[Practical approaches to the treatment of bacterial meningitis]. Antibiot Khimioter (2007) 0.75

[Acute rheumatic fever and Streptococcus group A tonsillitis: the current status of the problem and the questions of antibiotic therapy]. Antibiot Khimioter (2000) 0.75

[Shiga toxin production by Escherichia coli strains and antibiotics]. Antibiot Khimioter (2001) 0.75

[Ciprofloxacin in the treatment of intestinal infections of bacterial etiology]. Antibiot Khimioter (1997) 0.75

[Haemophilus influenzae antibiotic resistant strains isolated in Moscow in 2002-2004]. Antibiot Khimioter (2004) 0.75

[Clinicomicrobiological monitoring of patients with exacerbation of chronic bronchitis treated with antibacterial drugs]. Ter Arkh (2006) 0.75

[Molecular characteristic of methicillin-resistant Staphylococcus aureus strains isolated in Moscow clinics]. Mol Gen Mikrobiol Virusol (2010) 0.75

[The theoretical and practical aspects of the problem of antibiotic resistance]. Antibiot Khimioter (1992) 0.75

[A safety and reactogenicity study of experimentally produced batches of the brucellosis chemical vaccine with different methods for its application]. Zh Mikrobiol Epidemiol Immunobiol (1991) 0.75

[Characterization of antimicrobial properties of cefpirome]. Antibiot Khimioter (1996) 0.75

[Characteristics and clinical value of extended-spectrum beta-lactamases]. Antibiot Khimioter (2003) 0.75

[The future of clinical microbiology as a laboratory service]. Antibiot Khimioter (1999) 0.75

[Prospects for control of the occurence of antibiotic resistance]. Antibiot Khimioter (1998) 0.75

[Methicillin-resistant Staphylococci]. Antibiot Khimioter (1996) 0.75

[What is the future of antibacterial therapy?]. Antibiot Khimioter (1999) 0.75

[A comparative evaluation of the pharmacokinetics of different forms of benzathine benzylpenicillin]. Antibiot Khimioter (2000) 0.75

[Prospects of development of drugs for therapy of gram-positive bacterial infections]. Antibiot Khimioter (2000) 0.75

[In the commission on antibiotic policy]. Antibiot Khimioter (1998) 0.75

[Modern methods and means for the rapid determination of the sensitivity of the causative agents of dangerous infectious diseases to antibiotics and chemical preparations]. Voen Med Zh (1996) 0.75

[Cedex (ceftibuten)--a 3rd-generation cephalosporin for internal use]. Eksp Klin Farmakol (1996) 0.75

[Staphylococci and vancomycin--confrontation trends]. Antibiot Khimioter (2003) 0.75

[Bacterial beta-lactamases]. Antibiot Khimioter (1996) 0.75

[Cefoperazone and other third-generation cephalosporins]. Antibiot Khimioter (1992) 0.75

[Mechanisms of resistance to quinolones and current level of sensitivity of clinically important microorganisms to ofloxacin]. Antibiot Khimioter (1996) 0.75

[Combined antibacterial and probiotic therapy of Helicobacter-associated diseases in children]. Zh Mikrobiol Epidemiol Immunobiol (1999) 0.75

[Clinical strains of Burkholderia cepacia: characteristic and detection of the components in the quorum sensing regulatory system]. Mol Gen Mikrobiol Virusol (2003) 0.75

[Comparative activity of meropenem and other antibiotics against the pathogens of nosocomial infections]. Antibiot Khimioter (1998) 0.75

[Biological characteristic of the main pathogens in purulent bacterial meningitis]. Antibiot Khimioter (2002) 0.75

[The possibility of using chloride sodium, magnesium, and calcium-rich mineral water for the treatment of children with dysmetabolic nephropathy]. Vopr Kurortol Fizioter Lech Fiz Kult (2008) 0.75

[Efficient antimicrobial chemotherapy for skin and soft tissue infections]. Antibiot Khimioter (2003) 0.75

[Multicenter study of Staphylococcus susceptibility to antibiotics in Moscow and St. Petersburg]. Antibiot Khimioter (1998) 0.75

[The dynamics of the metabolic and functional activities of the immunocompetent cells in mice following immunization with different vaccines against Q fever]. Antibiot Khimioter (1993) 0.75

[Etiology of severe hospital infections in intensive care units and antibiotic resistance of pathogens]. Antibiot Khimioter (2005) 0.75

[Etiology and microbiological diagnosis of nosocomial pneumonia in newborns]. Antibiot Khimioter (2001) 0.75

[Oral cephalosporins in the treatment of suppurative-inflammatory diseases]. Antibiot Khimioter (1996) 0.75

[Molecular mechanisms of cephalosporin resistance in Gram-negative bacteria of the Enterobacteriaceae family]. Antibiot Khimioter (2004) 0.75

[Current problems of antibacterial therapy in rheumatology]. Vestn Ross Akad Med Nauk (1996) 0.75

[Synthesis and antibacterial activity of the new 9-aminoacridine, 10,11-dihydro-5H-dibenzo[b,f]azepine, polyfluoro 5,6-dihydro-1,3,5-oxadiazine derivatives]. Antibiot Khimioter (2001) 0.75

[The effect of the pathogenetic characteristics of an infection on the efficacy of chemotherapy]. Antibiot Khimioter (1992) 0.75

In vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antimicrobials: survey of Russian isolates. Int J Antimicrob Agents (1996) 0.75

[Cross and associated antibiotic resistance of gramnegative bacteria of the family Enterobacteriaceae resistant to the 3rd generation cephalosporins]. Antibiot Khimioter (2008) 0.75

[Microtest-system for detection of urinary tract infections]. Antibiot Khimioter (1995) 0.75

[Community-acquired pneumonia: standards for empirical antibacterial therapy]. Antibiot Khimioter (1999) 0.75

[Resistance of Russian isolates of Neisseria gonorrhoeae to fluoroquinolones]. Mol Gen Mikrobiol Virusol (2005) 0.75

[Genotypic emm-typing of streptococcal cultures, group A, isolated from patients with different clinical manifestations of streptococcal infection in Moscow]. Zh Mikrobiol Epidemiol Immunobiol (2005) 0.75

[Hospital infections caused by Pseudomonas aeruginosa. Significance in intensive therapy]. Anesteziol Reanimatol (1999) 0.75

[Evaluation of the usefulness of three collections of bacteriophages for typing methicillin-resistant Staphylococcus aureus, isolated in Moscow hospitals]. Zh Mikrobiol Epidemiol Immunobiol (2003) 0.75

[Aminopenicillins and beta-lactamase inhibitors]. Antibiot Khimioter (2006) 0.75

[Purulent meningitis in newborn infants (its etiology, pathogenesis, clinical picture, diagnosis, treatment)]. Antibiot Khimioter (2000) 0.75

[Azithromycin--an antibiotic of the azalide group]. Antibiot Khimioter (1993) 0.75